Redx Pharma PLC (LON:REDX) said it dosed the first three patients in its phase I clinical trial assessing RXC004 used alongside the Bristol Myers Squibb’s anti-PD-1 cancer drug OPDIVO.
The primary objective of the study is to evaluate the safety and tolerability of the regimen.
Results are expected in the second half of the year, which will be used to define dosing for a phase II clinical assessment of the combination, which is planned to get underway in the second half.
RXC004 taken on its own is currently in phase I with top-line results expected in mid-2021.
“We believe that RXC004 has the potential to offer clinical benefit both as a monotherapy and in combination with immunotherapies for patients with Wnt-driven advanced solid tumours,” said Redx chief executive Lisa Anson.